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aAbbreviations: CC50, concentration that causes a decrease of cell viability of 50%; Flu, influenza 
virus; FluA, influenza A virus; FluB, influenza B virus; MDCK, Mardin-Darby canine kidney; NP, 
nucleoprotein; PA, polymerase acidic protein; PB1, polymerase basic protein 1; PB2, polymerase 
basic protein 2; PPI, protein-protein interaction; PRA, plaque reduction assays; RBV, Ribavirin; 
RdRP, RNA-dependent RNA polymerase; RNP, ribonucleoprotein. 
 
ABSTRACT 
The limited number of drug classes licensed for treatment of influenza virus (Flu), together with the 
continuous emergence of viral variants and drug resistant mutants, highlight the urgent need to find 
antivirals with novel mechanisms of action. In this context, the viral RNA-dependent RNA 
polymerase (RdRP) subunits assembly has emerged as an attractive target. Starting from a 
cycloheptathiophene-3-carboxamide derivative recently identified by us for its ability to disrupt the 
interaction between the PA and PB1 subunits of RdRP, we have designed and synthesized a series 
of analogues. Their biological evaluation led to the identification of more potent protein-protein 
interaction inhibitors, endowed with antiviral activity that also encompassed a number of clinical 
isolates of FluA, including an oseltamivir-resistant strain, and FluB, without showing appreciable 
toxicity. From this study, the cycloheptathiophene-3-carboxamide scaffold emerged as particularly 
suitable to impart anti-Flu activity. 
 
INTRODUCTION 
The discovery of novel antiviral therapies1 and the continuing development of annual vaccines2 
have not yet led to an adequate treatment for influenza virus (Flua), an important pathogen 
responsible for both yearly seasonal epidemics and more extensive global pandemics. This issue 
was clearly evident during the unexpected emergence of the 2009 H1N1 pandemic strain by the 
reassortment of genes from human, pig, and bird's H1N1 viruses.3 This last pandemic, together with 
the on-going circulation of highly pathogenic avian H5N1 strains and the recent emergence of the 
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H7N9 virus, a new reassortant of avian origin isolated in China and associated with severe 
respiratory disease with 40% of mortality,4 which could potentially adapt for human-to-human 
transmission,5 highlighted the vulnerability of the world population to novel Flu strains. Although 
vaccination remains the main prophylactic strategy for controlling Flu infection, during the lagging 
time needed to produce a new vaccine and even during typical epidemic years, since vaccination 
does not prevent completely Flu infection, our only weapon against pandemic Flu are antivirals. 
Currently, only two classes of drugs have been approved by FDA for the treatment of Flu: the 
neuraminidase inhibitors oseltamivir and zanamivir, that are active on both influenza A (FluA) and 
influenza B (FluB) viruses, and the M2 channel blockers amantadine and rimantadine, whose 
spectrum of action is limited to FluA. Since Flu viruses have a high mutation rate, a major problem 
with both classes of drugs is the emergence of drug-resistant strains. Clearly, next-generation 
antivirals are needed to efficiently combat Flu, preferably with an innovative mechanism of action. 
The viral RNA-dependent RNA polymerase (RdRP) provides an attractive target6-9 given its 
functional essentiality for viral replication and involvement in virus pathogenicity.10-12 RdRP could 
be ideal for the development of new antivirals, since it is highly conserved among FluA, B, and C13 
while no homologue has been found in mammalian cells.6,8,13 RdRP is a complex of three subunits, 
polymerase acidic protein (PA), polymerase basic protein 1 (PB1), and polymerase basic protein 2 
(PB2), which are responsible for both transcription and replication.10,14-16 The assembly of the three 
subunits into functional viral RdRP is an essential step for influenza virus RNA synthesis and virus 
replication.17-19 Thus, the interference with its correct assembly through protein-protein interaction 
(PPI) inhibitors represents an attractive strategy to inhibit this enzyme. Although very 
challenging,20-23 the feasibility of such an approach has been demonstrated by the identification of 
antiviral peptides able to inhibit the PA-PB1 interaction.24-27 The recent publication of two 
crystallographic structures of a truncated form of PA bound to a PB1-derived peptide has shown 
that relatively few residues drive the binding of PB1 to PA,28,29 suggesting the potential for small 
molecule-mediated inhibition. The proof-of-principle that the PA-PB1 interaction can be indeed 
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disrupted also by small molecular-weight compounds was recently provided by us30-32 and few other 
authors.33,34 In our SBDD approach, an in silico screening of 3 million small molecules from the 
ZINC database, performed using one of the available crystal structures,28 led to the identification of 
32 virtual hits which were then evaluated in vitro for their ability to disrupt the PA-PB1 interaction. 
Five of them inhibited this interaction specifically and in a dose-dependent manner with IC50 values 
in the micromolar range,31 making all of them worthy of further investigation.   
In the present study, we attempted the structural optimization of thiophene-3-carboxamide 
derivative 1 (Figure 1, compound 10 in reference 31). This compound was able to disrupt the PA-
PB1 interaction in vitro with an IC50 of 90.7 µM and, even though it exhibited antiviral activity 
against FluA in infected cells at EC50 values slightly higher than 100 µM, its peculiar mechanism of 
action, coupled with the lack of cytotoxicity (CC50 > 250 µM) evaluated in two cell lines (Mardin-
Darby canine kidney (MDCK) and HEK 293T), made this compound a valid starting point. In an 
attempt to improve the ability to disrupt the PA-PB1 interaction and achieve a better anti-Flu 
activity, while maintaining the lack of toxicity, a number of structural modifications were 
undertaken synthesizing a series of analogues (compounds 2-36 in Table 1). Herein we report on 
their design, synthesis, and biological evaluation.  
 
DESIGN OF THIOPHENE-3-CARBOXAMIDE DERIVATIVES 
Compound 1 is made up of a tetrahydrocycloheptathiophene ring bearing at both the C-2 and C-3 
positions an amide moiety functionalized with an aromatic ring (Figure 1). The attention was 
mainly focused on modifying the o-fluorophenyl ring placed at the C-2 position, due to the higher 
synthetic accessibility. In particular, following the classical medicinal chemistry strategy, the o-
fluoro atom was eliminated (compound 2), shifted as in its positional isomers (compounds 3 and 4) 
as well as replaced by chlorine atom (compounds 5 and 6); dihalogen derivatives (compounds 7 and 
8) were also prepared. A cyclohexyl ring replaced the phenyl group in derivative 9. Then, the 
phenyl/cyclohexyl ring was spaced by inserting one or two methylenic units (compounds 10-16
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Additional derivatives were synthesized following the suggestions of a computational study 
performed using the same method that recently led us to identify a number of inhibitors of the 
PA/PB1 binding.31 The FLAP (Fingerprints for Ligands and Proteins) structure based virtual 
screening algorithm was recently used to identify a number of inhibitors of the PA/PB1 binding, 
using the x-ray crystallographic structure of the PA/PB1 complex28 as a template. 
Additional derivatives were synthesized following the suggestions of a computational study, 
performed using the Fingerprints for Ligands and Proteins (FLAP) algorithm. This method  recently 
led us to identify a number of inhibitors of the PA/PB1 binding,31  using the x-ray crystallographic 
structure of the PA/PB1 complex28 as a template. Although FLAP is not a classical docking 
procedure based on energy minimization, it allows to evaluate hypotheses on the binding mode of 
the screened compounds looking for the best overlap of the GRID Molecular Interaction Fields 
(MIFs), calculated for the protein cavity and for the ligand.35-37 Hydrophobic, hydrophilic and 
hydrogen-bond donor and acceptor interactions are considered. Since GRID MIFs are energy 
related, a high similarity between the MIFs of the protein and the ligands indicates an energy 
favored binding mode. 
Our previous study revealed the importance of hydrophobic interactions in the ligand-PA 
recognition process. 31  The green spots in Figure 2-A represent the hydrophobic regions in the PA 
cavity generated by GRID Force Field.38 The presence of those regions in the PA cavity is in 
agreement with the findings of Liu et al.39, who described the existence of three hydrophobic 
pockets. Indeed, one hydrophobic pocket is generated by W706 and P411, and is responsible for the 
binding of P5 from PB1. The second hydrophobic pocket is due to P710 and L666 interactions, and 
it is responsible for the binding of F9 from PB1. Finally, L640, V636, M595, and W619 are 
responsible for the third hydrophobic pocket, where L8 of PB1 is located. An additional 
hydrophobic spot is located in the middle of the cavity and mainly generated by the aliphatic chain 
of E623 and the protein backbone. The most favorable FLAP docking pose in the PA cavity for 
compound 1, is shown in Figure 2-B. Based on our model, compound 1 interacts with the first and 
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the second pockets and with the additional central hydrophobic region. From Figure 2-B one can 
reason that, in order to optimize the hydrophobic interactions to better fit the second pocket defined 
by Liu et al., the o-fluorophenyl ring at the C-2 position of compound 1 could be replaced with a 
bulkier aromatic substituent. In agreement with this hypothesis, a series of bicyclic heteroaromatic 
derivatives were designed looking for the best compromise between solubility and lipophilicity, 
according to the predicted values calculated using VolSurf+40.41 and the synthetic accessibility. 
Among the selected compounds, we synthesized 17 and 18 as first examples of such derivatives; 
their best poses are reported in Figures 2-C and 2-D. Compounds 1, 17, and 18 display a similar 
orientation, with the tetrahydrocycloheptathiophene moiety being oriented towards the W706 PA 
residue in the first pocket likely involving π–π interactions. The substituent in C-2 position is 
located in the second pocket, while the substituent in C-3 position fits the central hydrophobic spot. 
In addition, it must be noticed that, according to our modeling studies, all three compounds might 
be stabilized by a hydrogen bond between the oxygen of the C-2 amide group and the PA residue 
K643.  
To conclusively determine the role that the simultaneous presence of both the aromatic rings at C-2 
and C-3 positions plays on the biological activity, we synthesized the 2-amino derivative 19, which 
lacks the o-fluorobenzoyl moiety, and the primary amide 20, which lacks the C-3 pyridine ring. The 
ester and acid derivatives 21 and 22, analogues of 20, were also synthesized together with 
additional ethyl esters 23-26 and the corresponding acids 27-30, characterized by various 
substituents at the C-2 position. 
Few modifications involved the cycloheptane ring, whose size was reduced to cyclohexane and 
cyclopentane as in compounds 31 and 32, the direct analogues of 1, as well as in the C-3 variously 
functionalized derivatives 33-36. However, the increased toxicity, especially of the cyclohexane 
derivatives, has discouraged the synthesis of further analogues. 
 
CHEMISTRY 
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The synthesis of 2-[(substituted)amino]-N-(2-pyridinyl)thiophene-3-carboxamide derivatives 1-18, 
31, and 32 was accomplished, as outlined in Scheme 1, by applying the two-step Gewald 
synthesis.42,43 Thus, a first Knoevenagel condensation of various cycloalkyl ketones with 2-cyano-
N-pyridin-2-ylacetamide44 gave α,β-unsaturated nitriles. These intermediates were used without 
isolation in the successive cyclization step, performed in the presence of sulphur and N,N-
diethylamine in EtOH, to give derivatives 19, 37, and 38. The target compounds 1-16, 31, and 32 
were then obtained by a coupling reaction of these intermediates with the appropriate acyl chlorides 
in pyridine. Amide bond formation in derivatives 17 and 18 was carried out through an alternative 
procedure, by reacting intermediate 19 with quinolin-6-ylacetic acid and (3-methoxy-1-benzothien-
2-yl)acetic acid, respectively, in THF in the presence of 4-(4,6-dimethoxy-(1,3,5)-triazin-2-yl)-4-
methyl-morpholinium chloride (DMTMM)45 as activating agent.  
The starting materials for the preparation of the remaining derivatives were compounds 39-41,46 
42,47 and 43,42  that reacting with selected benzoyl chlorides gave thiophene-3-carboxamides 20, 
33,48 and 3448 and ethyl thiophene-3-carboxylates 21, 23, 24, 25,47 26, and 35,49 as shown in 
Scheme 2. The thiophene-3-carboxylic acids 22, 27-30, and 36 were then prepared by basic 
hydrolysis, starting from the corresponding ethyl esters.  
 
RESULTS AND DISCUSSION 
We started the study synthesizing and testing compound 1. The in-house synthesized 1 displayed 
biological activity comparable to that reported for the commercial derivative (compound 10 in 
reference 31). Indeed, it was endowed with a slightly lower PA-PB1 interaction inhibitory activity 
(IC50 = 145 µM) and a slightly higher anti-FluA activity in MDCK cells (EC50 = 90 µM); the in-
house synthesized 1 was used as comparative compound in all successive studies. 
The whole set of derivatives were evaluated for their ability to inhibit the physical interaction 
between PA and PB1 subunits by ELISA assays, including the PB1(1–15)–Tat peptide26 as a positive 
control. This peptide, which contains a synthetic PB1-derived peptide (amino acids 1–15) fused to 
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the translocating domain of HIV Tat protein, inhibited the PA–PB1 interaction with an apparent 
IC50 of 35 μM (Table 1). 
In parallel, for all the synthesized compounds the antiviral activity was tested in FluA virus-infected 
MDCK cells by plaque reduction assays (PRA) with the A/PR/8/34 (PR8) strain. Ribavirin (RBV), 
a known inhibitor of RNA viruses polymerase,50 was included as a positive control, exhibiting an 
EC50 of 8 μM (Table 1). 
To exclude that the observed antiviral activities could be due to toxic effects in the target cells, all 
the synthesized compounds were tested by MTT assays in two cell lines, i.e., MDCK and HEK 
293T (Table 1). RBV, included again as a reference compound, showed a CC50 value > 250 μM in 
both cell lines, as previously reported.51,52  
Looking at the activities shown in Table 1, it clearly appears that in some cases, such as in 
compounds 4-6 and 17-19, the structural modifications improved the ability of the analogues to 
inhibit the PA-PB1 interaction. In particular, compounds 6 and 19 were the most potent with IC50 
values of 32 and 35 μM, superimposable to that of the reference peptide. In addition, the 2-bycyclic 
derivatives 17 and 18, designed to improve the inhibitory efficiency of the hit 1 by increasing the 
hydrophobic interactions, defined by GRID MIFs, indeed proved to be better inhibitors, especially 
17, which exhibited an inhibitory activity 3-fold higher than that of compound 1. This finding can 
also be considered a validation of the suggested binding pose for compound 1. According to the 
FLAP docking pose reported in Figure 2, the different inhibitory activity among 1, 17, and 18 does 
not seem to correspond to a different binding mode of the compounds. However, considering that 
the three structures differ in the substituent at the C-2 position only, and that 17 possesses the most 
hydrophobic substituent in that position, this suggests that a stronger hydrophobic interaction could 
be the reason for a more difficult displacement of the compound, resulting in an increased activity.  
Since the -FLAP- structure-based approach proved to be successful to retrieve- and optimize ligand-
protein complexes,31,36 and in order to make a comparison with the binding modes hypothesized for 
the other PA/PB1 inhibitors, we inspected the possible FLAP docking poses for the most active 
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compounds, 6 and 19, in the PA cavity; results are shown in Figure 3. While for compounds 1, 17, 
and 18 reported in Figure 2 the most favorable poses were obtained upon interaction with the PA X-
ray conformation (i.e. structure 3CM8 after removal of PB1, thus in the most favorable pose for 
PB1 binding), the docking of 6 in the same cavity resulted to be unfavorable due to a steric 
hindrance between the p-chloro and the P710 residue, defining the second hydrophobic pocket. 
However, the analysis of the flexibility of P710 based on the dynamic studies previously reported31 
showed that this residue can rotate when the PA-PB1 complex is not formed. At the same time, 
W706, which is not directly involved in PB1 binding but represents the bottom of the second 
hydrophobic cavity, can freely rotate to further enlarge this sub-pocket. Using a more relaxed 
snapshot of the PA structure, having the P710 and of  W706 rotated to enlarge the second pocket 
(see Figure 3-A), 6 results to retain a strong π-π interaction with W706 and the p-chlorophenyl 
group of derivative 6 can fit the enlarged second pocket (Figure 3-B). Compound 6 can be further 
stabilized by R663 or K643 through H-bonds. A possible explanation of the high activity of 6 can 
be due to the presence of the p-chloro substituent that may induce a change in the position of 
residue P710. In this new position, P710 may interfere with the PA-PB1 interaction. Although an 
in-deep Molecular Dynamic investigation was not performed, this study led to hypothesize that 
conformational changes in the second hydrophobic pocket might play a role in the stabilization of 
the PA-ligand complex. 
The high PA-PB1 inhibitory activity found for the 2-amino derivative 19 represents an intriguing 
result, showing that the presence of a hydrophobic moiety in the C-2 position is even not essential 
for activity. Concerning the possible PA-19 interaction, the structural features of 19 do not allow 
the simultaneous binding to the three hydrophobic regions observed for compounds 1, 17, and 18. 
However, despite the analogy with the other docked compounds would suggest that 19 could 
occupy the first and the central hydrophobic pocket, the docking pose for this compound actually 
results to be flipped, with the pyridine group being located in the second pocket (Figure 3-C). To 
support this hypothesis, binding energies for compounds 6 and 19 displaying similar activity despite 
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structural differences, should be comparable. Indeed, the binding energies for the FLAP docked 
poses, evaluated using the GRID package, differ for 5 Kcal/mole. This behavior seems to suggest 
that the interaction with the second pocket rather than with the central pocket should be investigated 
to improve activity. PA residues that result to be involved in the binding of 19 are W706, I666, and 
P710. A H-bond with K643 could also occur. For the weak PA-PB1 inhibitors 2, 4, and 5, the 
FLAP  binding poses have been also inspected (Figure S1). Compounds 2 and 4 resulted to be 
similarly oriented, while for compound 5 the chlorine atom in ortho position of the phenyl group 
seems to induce a slightly different binding mode with weaker hydrophobic interaction, in 
agreement with the ELISA data. 
All the compounds able to inhibit PA-PB1 interaction were also active in inhibiting virus growth, 
with EC50 values ranging from 18 μM for compound 6 to 61 μM for compound 18. In addition, 
many of the compounds synthesized in this study were surprisingly endowed with antiviral activity 
in the micromolar range and at nontoxic concentrations, although they were inactive in vitro as PA-
PB1 inhibitors. Examining all the anti-influenza data reported in Table 1, some clues emerged. The 
cycloheptane ring of compound 1 cannot be replaced by smaller rings such as cyclohexane and 
cyclopentane; indeed, both derivatives 31 and 32 were inactive while displaying some cytotoxicity 
in 293T cells, more evident for the cyclohexane derivative 31 (CC50 = 60 μM). The unsuitability of 
smaller rings was also confirmed by the inactivity of the C-3 primary amides 33 and 34 and ester 
35. Once again, the cyclohexane derivative 33 showed a certain toxicity on both cell lines, with 
CC50 = 31 μM in 293T cells. 
Maintaining the N-pyridinyl-cycloheptathiophene-3-carboxamide, the o-fluorophenyl ring of 
compound 1 has been widely modified. The fluorine atom deletion (compound 2) as well as its 
shifting to the meta position (compound 3) were detrimental, while the p-fluoro derivative 4 was 
characterized by an increase in the inhibition of Flu replication (EC50 = 58 µM). The replacement of 
the fluorine atom with a chlorine was productive at the ortho position as in compound 5 (EC50 = 39 
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µM) but above all at the para position; indeed, compound 6 emerged as one of the most potent 
(EC50 = 18 µM) in agreement with the PA-PB1 inhibitory activity. The addition of another halogen 
atom permitted the activity to be maintained as in derivatives 7 and 8. The presence of the 
cyclohexane ring at the C-2 position improved the activity giving compound 9 with EC50 = 20 µM, 
which was, however, endowed with a slight cytotoxicity (CC50 = 180 µM). Excellent antiviral 
activity was obtained inserting a monomethylenic or dimethylenic chain between the C-2 amide 
moiety and the phenyl ring. Indeed, methylphenyl derivatives 10, 11, and 12, as well as the 
ethylphenyl analogues 13, 15, and 16, showed EC50 values ranging from 16 µM to 21 µM. On the 
contrary, spacing the cyclohexyl moiety from the C-2 position was deleterious, as 14 was inactive. 
The addition of a further aromatic ring at the C-2 position as in compounds 17 and 18 imparted a 
medium activity against virus replication, as expected by their anti-PA-PB1 activity. Notably, the 
deletion of the aromatic substituent from the C-2 position, as in the amino derivative 19, permitted 
to maintain a very good anti-Flu activity with an EC50 value of 26 µM, similar to that observed in 
the ELISA.  
When the 2-pyridine ring was deleted placing at the C-3 position a primary amide function, the 
antiviral activity disappeared (compound 20) and the same behaviour was shown by cyclopentane 
and cyclohexane analogues 33 and 34. On the other hand, all the ethyl cycloheptathiophene-3-
carboxylates 21, and 23-26, as well as the corresponding acids 22, and 27-30 possessed antiviral 
activity with EC50 values ranging from 43 µM to 95 µM. In general, the acid derivatives displayed a 
better activity than the ester analogues, with the p-chlorophenyl derivative 29 emerging once again 
as the best compound, with an EC50 value of 43 µM.  
Among all the synthesized compounds, p-chloro (compound 6), 2-amino (compound 19), and 
bicyclic derivatives (17 and 18), which exhibited the best inhibitory activity against both the PA-
PB1 interaction and viral growth, were selected for further investigations including RBV as a 
control.  
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First we evaluated the effects of the compounds in virus yield assays, where all the them showed 
good antiviral activity (Table 2). Then, we investigated whether their ability to disrupt the PA-PB1 
interaction in vitro correlated with the ability to interfere with the catalytic activity of FluA RdRP in 
a cellular context. To this end, a minireplicon assay was performed. 293T cells were cotransfected 
in the presence of the test compounds or DMSO with plasmids for the expression of influenza 
nucleoprotein (NP), PA, PB1, and PB2 proteins and the firefly luciferase RNA in negative-sense 
orientation, flanked by the noncoding regions of Flu A/WSN/33 segment 8. The expression of the 
firefly reporter gene indicates that a negative-sense RNA is synthesized and is reconstituted 
intracellularly into functional ribonucleoprotein (RNP) in which all four NP, PA, PB1, and PB2 
proteins are coexpressed and interact with each other. Table 2 shows that, with the exception of 
compound 18, all the thiophene-3-carboxamide derivatives had effect on FluA polymerase activity, 
with compound 6 showing an EC50 value of 10 μM, thus resulting slightly more effective than 
RBV. 
Finally, for the best derivatives, 6 and 19, we investigated the antiviral effects against a number of 
clinical isolates of FluA other than PR8. PRA were performed using influenza strains 
A/Parma/24/09 (H1N1), A/Wisconsin/67/05 (H3N2), and several pandemic swine-originated 
influenza virus (S-OIV) clinical isolates (H1N1). As shown in Table 3, the new derivatives 
effectively inhibited all FluA strains tested, of both H1N1 and H3N2 subtypes, including the 
oseltamivir-resistant clinical isolate (A/Parma/24/09). Compound 6 was slightly more potent than 
19, with EC50 values ranging from 15 to 23 µM. 
The same compounds were also assayed for their ability to inhibit the replication of FluB. When 
tested against Flu B/Lee/40 strain by PRA, compounds 6 and 19 were found to be effective against 
FluB, with EC50 values similar to those obtained with the FluA viruses (Table 3), thus displaying 
broad-spectrum anti-influenza activity.  
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CONCLUSIONS 
The viral RdRP is an attractive target to design new antivirals since it is highly conserved among 
Flu strains and no homologous has been found in mammalian cells. In particular, the disruption of 
its correct assembly through PPI inhibitors could be a promising strategy, although very few studies 
have been reported so far. Thanks to a SBDD approach, we recently identified a set of different 
small molecules able to disrupt PA-PB1 interaction and inhibit viral growth. In this study, some 
efforts have been pursued to evolve one of these molecules. Starting from thiophene-3-carboxamide 
derivative 1, more potent PA-PB1 inhibitors and anti-Flu derivatives have been achieved by mainly 
modifying the substituent placed at the C-2 position. Among these small molecules, compounds 6 
and 19 emerged as the most potent in inhibiting the physical interaction between the two viral 
subunits with IC50 values of 32 and 35 μM, better than the hit compound and comparable to that of 
the reference peptide. An in-depth investigation of the binding mode of the active 
cycloheptathiophene-3-carboxamide derivatives, although relevant to define the mechanism of 
inhibition, is out of the aim of this study. However, with the purpose to rationalize the inhibition 
data for the most potent PA-PB1 inhibitors, their FLAP-binding modes have been compared. Based 
on this analysis, the presence of the bulky halogen atom in para position of compound 6 might 
induce a different orientation of several residues in the PA cavity, making the competition with PB1 
more efficient. The good activity of 19, the only active compound that lacks the aromatic ring at the 
C-2 position, is more intriguing and deserves further exploration. However, modeling studies 
suggest that its docking pose results to be flipped with respect to that of the other compounds, with 
the pyridine group being located in the second hydrophobic pocket. This behavior seems to suggest 
that the interaction with the second pocket rather than with the central pocket should be investigated 
to improve activity. The last finding is supported by the promising activity displayed by compounds 
17 and 18, appositely designed to increase the interaction with the second pocket, according with 
the optimization of the hydrophobic GRID MIFs. The PPI inhibitory activity of 6 and 19 is 
preserved in the cellular context, where they showed a good inhibitory effect on FluA polymerase 
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activity and viral replication also encompassing a panel of clinically isolated strains, including a 
FluA oseltamivir-resistant, as well as FluB.  
An unexpected result coming from this study is the identification of many derivatives able to inhibit 
the viral growth without affecting PA-PB1 interaction in vitro. For these compounds, an alternative 
mechanism of action should exist and will be the object of future investigations. 
In conclusion, the cycloheptathiophene-3-carboxamide scaffold, when properly functionalized, 
emerged as particularly suitable to impart anti-Flu activity.  
 
EXPERIMENTAL SECTION 
Computational methods. The design of  larger compounds to optimize the hydrophobic interaction 
was performed using the FLAP approach35 previously used to identify inhibitors of the PA-PB1 
complex by virtual screening.31 The FLAP software is developed and licensed by Molecular 
Discovery Ltd. (www.moldiscovery.com). The docking procedure used by the FLAP algorithm 
generates the GRID Molecular Interaction Fields (MIFs) for the cavity and allows to visualize and 
quantify the hydrophobic and hydrophilic regions, as well as the regions where H-bond donors and 
acceptors might occur. Then, MIFs are also calculated for each ligand and FLAP docking poses are 
generated looking for the best overlap of the GRID MIFs of protein and those of the ligand. 
In this study, the main cavity of the crystallographic structure of a large C-terminal fragment of PA 
(aa 257-716) derived from the X-ray structure named 3CM828 was explored using the GRID force 
field.38 Using the PA cavity as a template, the design of new possible inhibitors was performed 
using FLAP in the structure-based mode,36,37 evaluating the best pose among 50 conformers for 
each candidate, as previously reported31 The probes used to generate the Molecular Interaction 
Fields were H (shape), DRY (hydrophobic interactions), N1 (H-bond donor) and O (H-bond 
acceptor) interactions. A second snapshot of the PA in a more relaxed form was used to dock 
compound 6; the method used to generate the new conformation of PA was previously reported.31 
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FLAP binding poses reported in this study underwent a mild optimization using Sybyl 2.0. Both 
ligand and surrounded PA residues were energy minimized using the Powell algorithm, with a 
convergence gradient ≤ 0.1 kcal/mol and a maximum of 5000 cycles. 
 
 
Chemistry 
All reactions were routinely checked by TLC on silica gel 60F254 (Merck) and visualized by using 
UV or iodine. Flash column chromatography separations were carried out on Merck silica gel 60 
(mesh 230-400). Melting points were determined in capillary tubes (Büchi Electrothermal Mod. 
9100) and are uncorrected. Elemental analyses were performed on a Fisons elemental analyzer, 
Model EA1108CHN, and the data for C, H, and N are within ± 0.4% of the theoretical values. 1H 
NMR and 13C NMR spectra were recorded at 200 MHz (Bruker Avance DPX-200) and 400 MHz 
(Bruker Avance DRX-400) using residual solvents such as chloroform ( = 7.26) or 
dimethylsulfoxide ( = 2.48) as an internal standard. Chemical shifts are given in ppm () and the 
spectral data are consistent with the assigned structures. Reagents and solvents were purchased from 
common commercial suppliers and were used as such. After extraction, organic solutions were 
dried over anhydrous Na2SO4, filtered, and concentrated with a Büchi rotary evaporator at reduced 
pressure. Yields are of purified product and were not optimized. All starting materials were 
commercially available unless otherwise indicated. Some of the compounds reported in this study, 
i.e., 1, 2, 20-24, 26-30, 32, and 36 are also commercially available, but being prepared by us and not 
reported in any previous reference, their synthesis is described below together with the description 
of the new derivatives.  
General procedure for the preparation of N-(2-pyridinyl)-2-aminothiophene-3-carboxamide 
derivatives (Method A). A mixture of 2-cyano-N-pyridin-2-ylacetamide44 (1.0 equiv), 
cyclopentanone, cyclohexanone, or cycloheptanone (4.0 equiv), ammonium acetate (1.3 equiv), and 
glacial acetic acid (3.5 equiv) in benzene was refluxed for 16 h in a Dean-Stark apparatus. After 
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cooling the reaction mixture was diluted with CHCl3 and washed with H2O, 10% Na2CO3 solution, 
and H2O. The organic phase was evaporated to dryness, affording to the crude Knoevenagel 
product, which was used in the next step without further purification. This material was dissolved in 
EtOH, added of sulphur (4.0 equiv) and N,N-diethylamine (4.0 equiv), and maintained at 40-50 °C 
for 1.5 h. After cooling, the reaction mixture was evaporated to dryness and purified by flash 
chromatography, eluting with EtOAc/cyclohexane (15%), and crystallized by EtOH.   
2-Amino-N-(2-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide (19). 
The title compound was prepared starting from cycloheptanone by Method A, in 59% yield: mp 
176-178 °C (dec); 1H-NMR (CDCl3) δ 1.70-1.90 (m, 6H, cycloheptane CH2), 2.60-2.70 and 2.80-
2.90 (m, each 2H, cycloheptane CH2), 4.80 (bs, 2H, NH2), 7.00 (dd, J = 1.1 and 7.0 Hz, 1H, 
pyridine CH), 7.70 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 8.10 (bs, 1H, NH), 8.25-8.30 (m, 2H, 
pyridine CH); 13C-NMR (CDCl3) δ 27.2, 27.5, 28.6, 29.2, 31.5, 113.6, 114.3, 119.2, 124.0, 135.0, 
138.8, 146.9, 151.5, 155.8, 164.4. Anal. (C15H17N3OS) C, H, N.  
2-Amino-N-(2-pyridinyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide (37). The title 
compound was prepared starting from cyclohexanone by Method A, in 41% yield: mp 158-159 °C; 
1H-NMR (CDCl3) δ 1.80-1.90 (m, 4H, cyclohexane CH2), 2.50-2.60 and 2.80-2.90 (m, each 2 H, 
cyclohexane CH2), 6.20 (bs, 2H, NH2), 7.00 (dd, J = 5.0 and 7.0 Hz, 1H, pyridine CH), 7.70 (dt, J = 
1.4 and 7.0 Hz, 1H, pyridine CH), 8.10 (bs, 1H, NH), 8.25-8.30 (m, 2H, pyridine CH); 13C-NMR 
(CDCl3) δ 22.8, 22.9, 24.5, 27.2, 108.5, 114.0, 119.1, 119.2, 128.5, 138.1, 147.8, 151.9, 160.8, 
164.4.  
2-Amino-N-(2-pyridinyl)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxamide (38). The 
title compound was prepared starting from cyclopentanone by Method A, in 46% yield: mp 159-160 
°C; 1H-NMR (CDCl3) δ 2.45 (q, J = 7.1 Hz, 2H, cyclopentane CH2), 2.80 and 3.10 (t, J = 7.1 Hz, 
each 2H, cyclopentane CH2), 6.25 (bs, 2H, NH2), 7.00 (dd, J = 5.0 and 7.0 Hz, 1H, pyridine CH), 
7.70 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 8.10 (bs, 1H, NH), 8.25-8.30 (m, 2H, pyridine CH); 
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13C-NMR (CDCl3) δ 27.4, 28.6, 30.7, 104.6, 113.7, 119.1, 122.5, 138.1, 138.2, 147.9, 151.8, 164.0, 
166.5.  
General procedure for C-2 amidation (Method B). A solution of the appropriate 2-
aminothiophene derivative (1.0 equiv) in pyridine was added of the suitable acyl chloride (2.0 
equiv). The reaction mixture was maintained at room temperature for 1 h, and worked up and 
purified as defined in the description of the compounds.  
2-[(2-Fluorobenzoyl)amino]-N-(2-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (1). The title compound was prepared starting from 19 by Method B, using 2-
fluorobenzoyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate 
which was filtered and purified by flash chromatography eluting with EtOAc/cyclohexane (15%) 
and then crystallized by EtOH, to give 1 in 42% yield: mp 206-209 °C; 1H-NMR δ 1.70-1.90 (m, 
6H, cycloheptane CH2), 2.70-2.75 and 2.95-300 (m, each 2H, cycloheptane CH2), 7.05 (ddd, J = 
0.9, 5.0 and 7.0 Hz, 1H, pyridine CH),  7.20 (dd, J = 8.3 and 12.0 Hz, 1H, aromatic CH), 7.30 (dt, J 
= 0.9 and 7.6 Hz, 1H, aromatic CH), 7.50 (dq, J = 1.4 and 7.3 Hz, 1H, aromatic CH), 7.70 (dt, J = 
1.4 and 7.0 Hz, 1H, pyridine CH), 8.10-8.20 (m, 2H, aromatic CH and NH), 8.20 (d, J = 4.4 Hz, 1H, 
pyridine CH), 8.30 (d, 1H, J = 8.4 Hz,  pyridine CH), 13.00 (d, J = 11.0 Hz, 1H, NH); 13C-NMR 
(CDCl3) δ 27.3, 27.6, 28.6, 29.0, 31.7, 114.3, 116.3 (d, JC-F = 23 Hz), 118.8, 119.8, 119.9, 124.9, 
132.1, 133.0, 133.2, 134.1 (d, JC-F = 9 Hz), 138.4, 141.4, 147.9, 151.2, 159.8, 160.6 (d, JC-F = 248 
Hz), 164.6. Anal. (C22H20FN3O2S) C, H, N. 
The physical-chemical properties are comparable to those of the commercial compound 
(STK063428) purchased from Vitas-M (Moscow, Russia) including the purity that is 100% for both 
the compounds, as assessed by UV chromatogram at 280 nm. 
2-(Benzoylamino)-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (2). The title compound was prepared starting from 19 by Method B, using benzoyl 
chloride. The reaction mixture was poured into ice/water obtained a precipitate which was filtered 
and purified by flash chromatography eluting with EtOAc/petroleum ether (15%) and then washed 
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with cyclohexane, to give 2 in 34% yield: mp 208-210 °C; 1H-NMR (DMSO d6) δ 1.45-1.70 (m, 
6H, cycloheptane CH2), 1.70-1.85 and 2.65-2.80 (m, each 2H, cycloheptane CH2), 7.05-7.10 (m, 
1H, pyridine CH), 7.40-7.60 (m, 3H, aromatic CH), 7.65-7.85 (m, 3H, aromatic CH and pyridine 
CH), 8.15 (d, J = 8.2 Hz, 1H, pyridine CH), 8.30 (d, J = 4.0 Hz, 1H, pyridine CH), 10.40 and 11.00 
(s, each 1H, NH). Anal. (C22H21N3O2S) C, H, N. 
2-[(3-Fluorobenzoyl)amino]-N-(2-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (3). The title compound was prepared starting from 19 by Method B, using 3-
fluorobenzoyl chloride. The reaction mixture was poured into ice/water and extracted with EtOAc. 
The organic layer was evaporated to dryness, obtaining a solid which was purified by flash 
chromatography eluting with EtOAc/cyclohexane (15%) and then crystallized by EtOH, to give 3 in 
39% yield: mp 215-216 °C; 1H-NMR (CDCl3) δ 1.75-1.80 (m, 6H, cycloheptane CH2), 1.85-1.90, 
2.80-2.85 and 3.00-3.05 (m, each 2H, cycloheptane CH2), 7.10 (ddd, J = 0.9, 5.0 and 7.0 Hz, 1H, 
pyridine CH), 7.30 (dt, J = 2.5 and 8.9 Hz, 1H, aromatic CH), 7.50 (dq, J = 2.5 and 5.5 Hz, 1H, 
aromatic CH), 7.70-7.80 (m, 3H, pyridine CH and aromatic CH), 8.25 (d, J = 4.4 Hz, 1H, pyridine 
CH), 8.30 (bs, 1H, NH), 8.35 (d, J = 8.3 Hz, 1H, pyridine CH), 12.00 (s, 1H, NH); 13C-NMR 
(CDCl3) δ 27.2, 27.5, 28.6, 29.1, 31.5, 114.3, 114.8 (d, JC-F = 28 Hz), 117.9, 119.3 (d, JC-F = 21 Hz), 
120.0, 122.7 (d, JC-F = 3 Hz), 130.5 (d, JC-F = 8 Hz), 132.8, 132.9, 134.9 (d, JC-F = 7 Hz), 138.3, 
142.8, 148.1, 151.0, 162.1, 162.9 (d, JC-F = 248 Hz), 164.9.  Anal. (C22H20FN3O2S) C, H, N. 
2-[(4-Fluorobenzoyl)amino]-N-(2-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (4). The title compound was prepared starting from 19 by Method B, using 4-
fluorobenzoyl chloride. The reaction mixture was poured into ice/water and extracted with EtOAc. 
The organic layer was evaporated to dryness, obtaining a solid which was purified by flash 
chromatography eluting with EtOAc/cyclohexane (15%), to give 4 in 44% yield: mp 192-193 °C; 
1H-NMR (CDCl3) δ 1.70-1.80 (m, 4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 3.00-3.05 (m, 
each 2H, cycloheptane CH2), 7.10 (ddd, J = 0.9 and 5.0 and 7.0 Hz, 1H, pyridine CH), 7.15-7.20 
(m, 2H, aromatic CH), 7.75 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 7.95-8.05 (m, 2H, aromatic 
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CH), 8.15-8.20 (m, 2H, pyridine CH and NH), 8.30 (d, J = 8.3 Hz, 1H, pyridine CH), 12.00 (s, 1H, 
NH); 13C-NMR (CDCl3) δ 27.2, 27.5, 28.5, 29.1, 31.5, 114.3, 115.9 (d, JC-F = 22 Hz), 117.6, 120.0, 
128.8, 129.9 (d, JC-F = 9 Hz), 132.6, 132.8, 138.3, 143.2, 148.1, 151.0, 162.3, 163.9, 165.2 (d, JC-F = 
252 Hz), 166.5. Anal. (C22H20FN3O2S) C, H, N. 
2-[(2-Chlorobenzoyl)amino]-N-(2-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (5). The title compound was prepared starting from 19 by Method B, using 2-
chlorobenzoyl chloride. The reaction mixture was poured into ice/water and extracted with EtOAc. 
The organic layer was evaporated to dryness, obtaining a solid which was purified by flash 
chromatography eluting with EtOAc/cyclohexane (15%) and then crystallized by EtOH, to give 5 in 
31% yield: mp 160-161 °C; 1H-NMR (CDCl3) δ 1.65-1.75 (m, 4H, cycloheptane CH2), 1.85-1.90, 
2.75-2.80 and 2.90-2.95 (m, each 2H, cycloheptane CH2), 7.05 (ddd, J = 0.9 and 5.0 and 7.0 Hz, 
1H, pyridine CH), 7.30-7.45 (m, 3H, aromatic CH), 7.70 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 
7.75 (dd, J = 1.6 and 7.5 Hz, 1H, aromatic CH), 8.15 (d, J = 4.4 Hz, 1H, pyridine CH), 8.25 (d, J = 
8.3 Hz, 1H, pyridine CH), 8.40 (bs, 1H, NH), 11.40 (s, 1H, NH); 13C-NMR (CDCl3) δ 27.3, 27.5, 
28.6, 29.0, 31.7, 114.2, 118.8, 120.0, 127.1, 130.6, 130.7, 131.4, 132.0, 133.0, 133.1, 133.3, 138.3, 
141.4, 148.0, 151.1, 162.8, 164.6. Anal. (C22H20ClN3O2S) C, H, N. 
2-(4-Chlorobenzamido)-N-(pyridin-2-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (6). The title compound was prepared starting from 19 by Method B, using 4-
chlorobenzoyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate 
which was filtered and purified by flash chromatography eluting with EtOAc/cyclohexane (20%), to 
give 6 in 29% yield: mp 222-223 °C; 1H-NMR (CDCl3) δ 1.70-1.80 (m, 4H, cycloheptane CH2), 
1.85-1.90, 2.75-2.80 and 3.00-3.05 (m, each 2H, cycloheptane CH2), 7.10 (ddd, J = 0.9 and 5.0 and 
7.0 Hz, 1H, pyridine CH), 7.45 (d, J = 8.4 Hz, 2H, aromatic CH), 7.75 (dt, J = 1.4 and 7.0 Hz, 1H, 
pyridine CH), 7.90 (d, J = 8.4 Hz, 2H, aromatic CH), 8.10 (bs, 1H, NH), 8.25-8.30 (m, 2H, pyridine 
CH), 12.00 (s, 1H, NH). Anal. (C22H20ClN3O2S) C, H, N. 
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2-[(2-Chloro-4-fluorobenzoyl)amino]-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (7). The title compound was prepared starting from 19 by 
Method B, using 2-chloro-4-fluorobenzoyl chloride. The reaction mixture was poured into ice/water 
obtaining a precipitate which was filtered and purified by flash chromatography eluting with 
EtOAc/cyclohexane (15%), to give 7 in 25% yield: mp 162-163 °C; 1H-NMR (CDCl3) δ 1.70-1.80 
(m, 4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 3.00-3.05 (m, each 2H, cycloheptane CH2), 
7.05-7.15 (m, 2H, aromatic CH and pyridine CH), 7.20 (dd, J = 2.4 and 8.4 Hz, 1H, aromatic CH), 
7.70 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 7.80 (dd, J = 6.0 and 8.4 Hz, 1H, aromatic CH), 8.00 
(bs, 1H, NH), 8.20 (d, J = 8.4 Hz, 1H, pyridine CH), 8.30 (d, J = 4.6 Hz, 1H, pyridine CH), 11.50 
(s, 1H, NH). Anal. (C22H19ClFN3O2S) C, H, N. 
2-[(2,4-Dichlorobenzoyl)amino]-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (8). The title compound was prepared starting from 19 by 
Method B, using 2,4-dichlorobenzoyl chloride. The reaction mixture was poured into ice/water 
obtaining a precipitate which was filtered and crystallized by EtOH, to give 8 in 30% yield: mp 
190-191 °C; 1H-NMR (CDCl3) δ 1.70-1.80 (m, 4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 
3.00-3.05 (m, each 2H, cycloheptane CH2), 7.05 (ddd, J = 0.9 and 5.0 and 7.0 Hz, 1H, pyridine 
CH), 7.35 (dd, J = 1.8 and 8.4 Hz, 1H, aromatic CH), 7.45 (d, J = 1.8 Hz, 1H, aromatic CH), 7.65-
7.75 (m, 2H, aromatic CH and pyridine CH), 8.10 (bs, 1H, NH), 8.20-8.25 (m, 2H, pyridine CH), 
11.50 (s, 1H, NH). Anal. (C22H19Cl2N3O2S) C, H, N. 
2-[(Cyclohexylcarbonyl)amino]-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-
3-carboxamide (9). The title compound was prepared starting from 19 by Method B, using 
cyclohexanecarbonyl chloride. The reaction mixture was poured into ice/water obtained a 
precipitate which was filtered and purified by flash chromatography eluting with EtOAc/petroleum 
ether (15%) to give 9 in 20% yield: mp 201-204 °C; 1H-NMR (DMSO d6) δ 1.00-1.80 (m, 17H, 
cyclohexane CH2, cyclohexane CH, and cycloheptane CH2), 2.50-2.65 (m, 4H, cycloheptane CH2), 
7.05 (dd, J = 5.0 and 7.3 Hz, 1H, pyridine CH), 7.75 (dt, J = 2.0 and 9.2 Hz, 1H, pyridine CH), 8.10 
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(d, J = 8.1 Hz, 1H, pyridine CH), 8.25 (d, J = 3.6 Hz, 1H, pyridine CH), 10.20 and 10.30 (s, each 
1H, NH). Anal. (C22H27N3O2S) C, H, N. 
2-{[(4-Fluorophenyl)acetyl]amino}-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (10). The title compound was prepared starting from 19 
by Method B, using (4-fluorophenyl)acetyl chloride. The reaction mixture was poured into 
ice/water obtaining a precipitate which was filtered and purified by flash chromatography eluting 
with EtOAc/cyclohexane (15%), to give 10 in 25% yield: mp 159-160 °C; 1H-NMR (CDCl3) δ 
1.60-1.70 (m, 4H, cycloheptane CH2), 1.80-1.85, 2.70-2.75 and 2.90-2.95 (m, each 2H, 
cycloheptane CH2), 3.75 (s, 2H, CH2), 7.00-7.10 (m, 3H, aromatic CH and pyridine CH), 7.30-7.35 
(m, 2H, aromatic CH), 7.70 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 7.90 (bs, 1H, NH), 8.15 (d, J 
= 8.3 Hz, 1H, pyridine CH), 8.25 (d, J = 4.6 Hz, 1H, pyridine CH), 10.75 (s, 1H, NH). Anal. 
(C23H22FN3O2S) C, H, N. 
2-{[(4-Chlorophenyl)acetyl]amino}-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (11). The title compound was prepared starting from 19 
by Method B, using (4-chlorophenyl)acetyl chloride. The reaction mixture was poured into 
ice/water obtaining a precipitate which was filtered and purified by flash chromatography eluting 
with EtOAc/cyclohexane (15%), to give 11 in 27% yield: mp 169-170 °C; 1H-NMR (CDCl3) δ 
1.60-1.70 (m, 4H, cycloheptane CH2), 1.80-1.85, 2.70-2.75 and 2.90-2.95 (m, each 2H, 
cycloheptane CH2), 3.75 (s, 2H, CH2), 7.05 (ddd, J = 0.9, 5.0 and 7.0 Hz, 1H, pyridine CH), 7.25 
and 7.30 (d, J = 8.3 Hz, each 2H, aromatic CH), 7.75 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 
7.85 (bs, 1H, NH), 8.15 (d, J = 8.3 Hz, 1H, pyridine CH), 8.25 (d, J = 4.6 Hz, 1H, pyridine CH), 
10.75 (s, 1H, NH). Anal. (C23H22ClN3O2S) C, H, N. 
2-[(Phenylacetyl)amino]-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (12). The title compound was prepared starting from 19 by Method B, using 
phenylacetyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate which 
was filtered and purified by flash chromatography eluting with EtOAc/cyclohexane (15%), and then 
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crystallized by EtOH, to give 12 in 20% yield: mp 165-167 °C; 1H-NMR (CDCl3) δ 1.60-1.70 (m, 
4H, cycloheptane CH2), 1.80-1.85, 2.70-2.75 and 2.90-2.95 (m, each 2H, cycloheptane CH2), 3.75 
(s, 2H, CH2), 7.10 (ddd, J = 0.9, 5.0 and 7.0 Hz, 1H, pyridine CH), 7.25-7.40 (m, 5H, aromatic CH), 
7.75 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 8.15-8.20 (m, 2H, pyridine CH), 8.40 (bs, 1H, NH), 
10.75 (s, 1H, NH). Anal. (C23H23N3O2S) C, H, N. 
2-{[3-(4-Fluorophenyl)propanoyl]amino}-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (13). The title compound was prepared starting from 19 
by Method B, using 3-(4-fluorophenyl)propanoyl chloride. The reaction mixture was poured into 
ice/water obtaining a precipitate which was filtered and crystallized twice by EtOH, to give 13 in 
24% yield: mp 132-133 °C; 1H-NMR (CDCl3) δ 1.60-1.70 (m, 4H, cycloheptane CH2), 1.80-1.85 
(m, 2H, cycloheptane CH2), 2.70-2.75 and 2.90-3.00 (m, each 4H, cycloheptane CH2 and CH2CH2), 
6.85-6.95 (m, 2H, aromatic CH and pyridine CH), 7.10-7.20 (m, 3H, aromatic CH), 7.80 (dt, J = 1.4 
and 7.0 Hz, 1H, pyridine CH), 8.20 (d, J = 8.3 Hz, 1H, pyridine CH), 8.30 (d, J = 4.6 Hz, 1H, 
pyridine CH), 8.75 (bs, 1H, NH), 10.70 (s, 1H, NH). Anal. (C24H24FN3O2S) C, H, N. 
2-[(Cyclohexylacetyl)amino]-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxamide (14). The title compound was prepared starting from 19 by Method B, using 
cyclohexylacetyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate 
which was filtered and crystallized twice by EtOH, to give 14 in 38% yield: mp 181-182 °C (dec); 
1H-NMR (CDCl3) δ 0.95-1.30 (m, 5H, cyclohexane CH2), 1.60-1.75 (m, 10H, cycloheptane CH2 
and cyclohexane CH2), 1.80-1.85 (m, 2H, cycloheptane CH2), 2.25 (d, J = 7.0 Hz, 2H, CH2), 2.70-
2.75 and 2.95-3.00 (m, each 2H, cycloheptane CH2), 7.10-7.20, 7.75-7.80, and 8.20-8.25 (m, each 
1H, pyridine CH), 8.30 (d, J = 4.6 Hz, 1H, pyridine CH), 8.45 (bs, 1H, NH), 10.75 (s, 1H, NH). 
Anal. (C23H29N3O2S) C, H, N. 
2-{[3-(4-Chlorophenyl)propanoyl]amino}-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (15). The title compound was prepared starting from 19 
by Method B, using 3-(4-chlorophenyl)propanoyl chloride. The reaction mixture was poured into 
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ice/water obtaining a precipitate which was filtered and purified by flash chromatography eluting 
with EtOAc/cyclohexane (15%), and then crystallized by EtOH, to give 15 in 42% yield: mp 125-
126 °C; 1H-NMR (CDCl3) δ 1.60-1.70 (m, 4H, cycloheptane CH2), 1.80-1.85 (m, 2H, cycloheptane 
CH2), 2.70-2.75 (m, 4H, cycloheptane CH2 and CH2CH2), 2.80-2.85 (m, 2H, cycloheptane CH2), 
3.00 (t, J = 7.5 Hz, 2H, CH2CH2), 7.10 (ddd, J = 0.9, 5.0 and 7.0 Hz, 1H, pyridine CH), 7.05-7.10 
and 7.15-7.20 (m, each 2H, aromatic CH), 7.75 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 8.20 (d, J 
= 8.3 Hz, 1H, pyridine CH), 8.25 (d, J = 4.6 Hz, 1H, pyridine CH), 8.40 (bs, 1H, NH), 10.75 (s, 1H, 
NH). Anal. (C24H24ClN3O2S) C, H, N. 
2-[(3-Phenylpropanoyl)amino]-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-
3-carboxamide (16). The title compound was prepared starting from 19 by Method B, using 3-
phenylpropanoyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate 
which was filtered and purified by flash chromatography eluting with EtOAc/cyclohexane (15%), 
and then crystallized by EtOH, to give 16 in 28% yield: mp 135-136 °C; 1H-NMR (CDCl3) δ 1.60-
1.70 (m, 4H, cycloheptane CH2), 1.80-1.85 (m, 2H, cycloheptane CH2), 2.70-2.75 (m, 4H, 
cycloheptane CH2 and CH2CH2), 2.80-2.85 (m, 2H, cycloheptane CH2), 3.00 (t, J = 7.5 Hz, 2H, 
CH2CH2), 7.10-7.25 (m, 6H, aromatic CH and pyridine CH), 7.85 (dt, J = 1.4 and 7.0 Hz, 1H, 
pyridine CH), 8.20 (d, J = 8.3 Hz, 1H, pyridine CH), 8.30 (d, J = 4.6 Hz, 1H, pyridine CH), 8.75 
(bs, 1H, NH), 10.70 (s, 1H, NH). Anal. (C24H25N3O2S) C, H, N. 
N-Pyridin-2-yl-2-[(quinolin-6-ylacetyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-
3-carboxamide (17). To a solution of 19 (0.5 g, 1.75 mmol) in THF (40 mL) was added quinolin-6-
ylacetic acid (0.3 g, 1.59 mmol) and DMTMM45. After 24 h, the reaction mixture was poured into 
ice/water obtaining a precipitate which was filtered and crystallized by cyclohexane/EtOAc, to give 
17 (0.4 g, 55%): mp 122-123 °C; 1H-NMR (CDCl3) δ 1.50-1.55 (m, 4H, cycloheptane CH2), 1.55-
2.00, 2.40-2.60, and 2.80-3.00 (m, each 2H, cycloheptane CH2), 3.90 (s, 2H, CH2), 7.00-7.10 (m, 
1H, pyridine CH), 7.25 (s, 1H, quinoline CH), 7.40-7.50 (m, 1H, quinoline CH), 7.60-7.75 (m, 2H, 
quinoline CH and pyridine CH), 7.85 (s, 1H, quinoline CH), 7.95 (d, J = 8.0 Hz, 1H, quinoline CH), 
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8.10-8.30 (m, 3H, quinoline CH and pyridine CH), 9.00 and 11.00 (s, each 1H, NH). Anal. 
(C26H24N4O2S) C, H, N. 
2-{[(3-Methoxy-1-benzothien-2-yl)acetyl]amino}-N-pyridin-2-yl-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide (18). The title compound was prepared by using the same 
procedure used for the synthesis of 17 replacing quinolin-6-ylacetic acid with (3-methoxy-1-
benzothien-2-yl)acetic acid, in 16% yield after purification by flash chromatography eluting with 
EtOAc/cyclohexane (20%): mp 153-155 °C; 1H-NMR (DMSO d6) δ 1.50-1.70 (m, 4H, 
cycloheptane CH2), 1.75-1.80 (m, 2H, cycloheptane CH2), 2.60-2.70 (m, 4H, cycloheptane CH2), 
3.85 (s, 3H, OCH3), 4.00 (s, 2H, CH2), 7.05-7.15 (m, 1H, pyridine CH), 7.30-7.40 (m, 2H, 
benzothiene CH), 7.65-7.70 (m, 1H, pyridine CH), 7.75-7.90 (m, 2H, benzothiene CH), 1.15 (d, J = 
8.36 Hz, 1H, pyridine CH), 8.25-8.30 (m, 1H, pyridine CH), 10.45 and 10.70 (s, each 1H, NH). 
Anal. (C26H25N3O3S) C, H, N. 
2-[(2-Fluorobenzoyl)amino]-N-(2-pyridinyl)-4,5,6,7-tetrahydro-1-benzothiophene-3-
carboxamide (31). The title compound was prepared starting from 37 by Method B, using 2-
fluorobenzoyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate 
which was filtered and purified by flash chromatography eluting with EtOAc/cyclohexane (15%), to 
give 31 in 35% yield: 204-205 °C; 1H-NMR (CDCl3) δ 1.80-1.90 (m, 4H, cyclohexane CH2), 2.70-
2.75 and 2.85-2.90 (m, each 2H, cyclohexane CH2), 7.05 (dd, J = 5.0 and 7.0 Hz, 1H, pyridine CH),  
7.20 (dd, J = 8.3 and 12.0 Hz, 1H, aromatic CH), 7.30 (t, J = 7.6 Hz, 1H, aromatic CH), 7.50 (dq, J 
= 1.4 and 7.3 Hz, 1H, aromatic CH), 7.70 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 8.20 (dt, J = 
1.4 and 7.7 Hz, 1H, aromatic CH), 8.25 (d, J = 4.4 Hz, 1H, pyridine CH), 8.30-8.35 (m, 2H, 
pyridine CH and NH), 13.00 (d, J = 11.0 Hz, 1H, NH); 13C-NMR (CDCl3) δ 22.5, 22.9, 24.3, 26.7, 
114.5, 115.1, 116.4 (d, JC-F = 23 Hz), 119.8, 120.1 (d, JC-F = 11 Hz), 124.8 (d, JC-F = 3 Hz), 127.0, 
128.8, 132.1, 134.1 (d, JC-F = 9 Hz), 138.3, 146.3, 147.9, 151.2, 160.0, 160.7 (d, JC-F = 249 Hz) 
164.2. Anal. (C21H18FN3O2S) C, H, N. 
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2-[(2-Fluorobenzoyl)amino]-N-(2-pyridinyl)-5,6-dihydro-4H-cyclopenta[b]thiophene-3-
carboxamide (32). The title compound was prepared starting from 38 by Method B, using 2-
fluorobenzoyl chloride. The reaction mixture was poured into ice/water and extracted with EtOAc. 
The organic layer was evaporated to dryness, obtaining a solid which was purified by flash 
chromatography eluting with EtOAc/cyclohexane (15%) and then crystallized by EtOH, to give 32 
in 37% yield: mp 184-185 °C; 1H-NMR (CDCl3) δ 2.55 (q, J = 7.1 Hz, 2H, cyclopentane CH2), 2.80 
and 3.20 (t, J = 7.1 Hz, each 2H, cyclopentane CH2), 7.00 (dd, J = 5.0 and 7.0 Hz, 1H, pyridine 
CH), 7.20 (dd, J = 8.3 and 12.0 Hz, 1H, aromatic CH), 7.30 (t, J = 7.6 Hz, 1H, aromatic CH), 7.55 
(dq, J = 1.4 and 7.3 Hz, 1H, aromatic CH), 7.70 (dt, J = 1.4 and 7.0 Hz, 1H, pyridine CH), 8.20 (dt, 
J = 1.4 and 7.7 Hz, 1H, aromatic CH), 8.25 (d, J = 4.4 Hz, 1H, pyridine CH), 8.30-8.35 (m, 2H, 
pyridine CH and NH), 13.00 (d, J = 11.0 Hz, 1H, NH); 13C-NMR (CDCl3) δ 28.2, 28.6, 30.3, 111.2, 
114.2, 116.4 (d, JC-F = 23 Hz), 119.8, 120.0, 124.8 (d, JC-F = 3 Hz), 132.1, 134.2 (d, JC-F = 9 Hz), 
134.4, 137.1, 138.2, 148.0, 150.9, 151.2, 159.9, 160.7 (d, JC-F = 249 Hz), 163.6. Anal. 
(C20H16FN3O2S) C, H, N. 
2-[(2-Fluorobenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide 
(20). The title compound was prepared starting from 2-amino-5,6,7,8-tetrahydro-4H-
cyclohepta[b]thiophene-3-carboxamide 3946 by Method B, using 2-fluorobenzoyl chloride. The 
reaction mixture was poured into ice/water obtaining a precipitate which was filtered and 
crystallized by EtOH, to give 20 in 40% yield: mp 233-234 °C; 1H-NMR (CDCl3) δ 1.60-1.70 (m, 
4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 2.85-2.90 (m, each 2H, cycloheptane CH2), 5.75 
(bs, 2H, NH2), 7.20 (dd, J = 8.3 and 12.0 Hz, 1H, aromatic CH), 7.30 (dt, J = 0.9 and 7.6 Hz, 1H, 
aromatic CH), 7.50 (dq, J = 1.4 and 7.3 Hz, 1H, aromatic CH), 8.25 (dt, J = 1.7 and 7.8 Hz, 1H, 
aromatic CH),  12.25 (d, J = 11.0 Hz, 1H, NH); 13C-NMR (CDCl3) δ 27.1, 27.6, 28.5, 28.8, 31.7, 
116.3 (d, JC-F = 23 Hz), 117.5, 121.8, 124.8 (d, JC-F = 3 Hz), 132.1, 132.6, 133.4, 134.0 (d, JC-F = 9 
Hz), 141.8, 159.8, 160.7 (d, JC-F = 249 Hz), 168.2. Anal. (C17H17FN2O2S) C, H, N. 
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Ethyl 2-[(2-fluorobenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxylate (21). The title compound was prepared starting from ethyl 2-amino-5,6,7,8-tetrahydro-
4H-cyclohepta[b]thiophene-3-carboxylate 4247 by Method B, using 2-fluorobenzoyl chloride. The 
reaction mixture was poured into ice/water obtaining a precipitate which was filtered and 
crystallized by EtOH, to give 21 in 100% yield: mp 117-118 °C; 1H-NMR (CDCl3) δ 1.30 (t, J = 7.1 
Hz, 3H, CH2CH3), 1.60-1.70 (m, 4H, cycloheptane CH2), 1.80-1.85, 2.70-2.75 and 3.05-3.10 (m, 
each 2H, cycloheptane CH2), 4.35 (q, J = 7.1 Hz, 2H, CH2CH3), 7.20 (dd, J = 8.3 and 12.0 Hz, 1H, 
aromatic CH), 7.35 (dt, J = 0.9 and 7.6 Hz, 1H, aromatic CH), 7.55 (dq, J = 1.4 and 7.3 Hz, 1H, 
aromatic CH), 8.20 (dt, J = 1.7 and 7.8 Hz, 1H, aromatic CH),  12.25 (d, J = 11.0 Hz, 1H, NH); 13C-
NMR (CDCl3) δ 14.3, 26.9, 27.8, 28.2, 28.6, 32.2, 60.7, 114.0, 116.3 (d, JC-F = 24 Hz), 119.9 (d, JC-
F = 11 Hz), 124.9 (d, JC-F = 3 Hz), 131.7, 132.2 (d, JC-F = 1 Hz), 134.1 (d, JC-F = 9 Hz), 137.0, 
144.5, 159.7 (d, JC-F = 3 Hz), 160.6 (d, JC-F = 248 Hz), 166.1. Anal. (C19H20FNO3S) C, H, N. 
Ethyl 2-[(4-fluorobenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxylate (23). The title compound was prepared starting from 4247 by Method B, using 4-
fluorobenzoyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate 
which was filtered and crystallized by EtOH, to give 23 in 64% yield: mp 117-118 °C; 1H-NMR 
(CDCl3) δ 1.35 (t, J = 7.1 Hz, 2H, CH2CH3), 1.60-1.70 (m, 4H, cycloheptane CH2), 1.80-1.85, 2.70-
2.75 and 3.05-3.10 (m, each 2H, cycloheptane CH2), 4.35 (q, J = 7.1 Hz, 3H, CH2CH3), 7.10-7.20 
and 7.95-8.05 (m, each 2H, aromatic CH), 12.25 (s, 1H, NH). Anal. (C19H20FNO3S) C, H, N. 
Ethyl 2-[(2-chlorobenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxylate (24). The title compound was prepared starting from 4247 by Method B, using 2-
chlorobenzoyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate 
which was filtered and crystallized by EtOH, to give 24 in 46% yield: mp 91-92 °C; 1H-NMR 
(CDCl3) δ 1.35 (t, J = 7.1 Hz, 2H, CH2CH3), 1.60-1.70 (m, 4H, cycloheptane CH2), 1.80-1.85, 2.70-
2.75 and 3.05-3.10 (m, each 2H, cycloheptane CH2), 4.30 (q, J = 7.1 Hz, 3H, CH2CH3), 7.30-7.45 
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(m, 3H, aromatic CH), 7.75 (dd, J = 1.5 and 7.5 Hz, 1H, aromatic CH), 11.80 (s, 1H, NH). Anal. 
(C19H20ClNO3S) C, H, N. 
Ethyl 2-[(4-methoxybenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-
carboxylate (26). The title compound was prepared starting from 4247 by Method B, using 4-
methoxybenzoyl chloride. The reaction mixture was poured into ice/water obtaining a precipitate 
which was filtered and crystallized by EtOH, to give 26 in 45% yield: mp 127-128 °C; 1H-NMR 
(CDCl3) δ 1.45 (t, J = 7.1 Hz, 3H, CH2CH3), 1.60-1.70 (m, 4H, cycloheptane CH2), 1.80-1.85, 2.70-
2.75 and 3.05-3.10 (m, each 2H, cycloheptane CH2), 3.85 (s, 3H, CH3), 4.35 (q, J = 7.1 Hz, 2H, 
CH2CH3), 6.95.7.00 and 7.90-7.95 (m, each 2H, aromatic CH), 12.10 (s, 1H, NH). Anal. 
(C20H23NO4S) C, H, N. 
General procedure for hydrolysis (Method C). A suspension of the appropriate ethyl thiophene-
3-carboxylate (1.0 equiv) and LiOH (4.0 equiv) in a mixture H2O/THF (1:1) was maintained at 50 
°C for 48 h. After cooling the reaction mixture was acidified (pH 6) with 2N HCl and the precipitate 
was filtered, washed with water and crystallized by EtOH. 
2-[(2-Fluorobenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid 
(22). The title compound was prepared starting from 21 by Method C in 65% yield: mp 186-187 °C; 
1H-NMR (CDCl3) δ 1.60-1.70 (m, 4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 3.15-3.20 (m, 
each 2H, cycloheptane CH2), 7.20 (dd, J = 8.3 and 12.0 Hz, 1H, aromatic CH), 7.35 (dt, J = 0.9 and 
7.6 Hz, 1H, aromatic CH), 7.55 (dq, J = 1.4 and 7.3 Hz, 1H, aromatic CH), 8.20 (dt, J = 1.7 and 7.8 
Hz, 1H, aromatic CH),  12.25 (d, J = 11.0 Hz, 1H, NH); 13C-NMR (CDCl3) δ  27.0, 27.7, 27.9, 28.6, 
32.3, 112.8, 116.3 (d, JC-F = 24 Hz), 119.7 (d, JC-F = 10 Hz), 125.0 (d, JC-F = 3 Hz), 132.0, 132.4, 
134.3 (d, JC-F = 9 Hz), 137.5, 146.7, 159.7, 160.6 (d, JC-F = 248 Hz), 170.4.  Anal. (C17H16FNO3S) 
C, H, N. 
2-[(4-Fluorobenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid 
(27). The title compound was prepared starting from 23 by Method C in 33% yield: mp 205-206 °C 
(dec.); 1H-NMR (CDCl3) δ 1.60-1.70 (m, 4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 3.15-
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3.20 (m, each 2H, cycloheptane CH2), 7.20-7.30 and 7.95-8.05 (m, each 2H, aromatic CH), 12.00 
(s, 1H, NH). Anal. (C17H16FNO3S) C, H, N. 
2-[(2-Chlorobenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid 
(28). The title compound was prepared starting from 24 by Method C in 39% yield: mp  226-227 °C 
(dec.); 1H-NMR (CDCl3) δ 1.60-1.70 (m, 4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 3.15-
3.20 (m, each 2H, cycloheptane CH2), 7.35-7.45 (m, 3H, aromatic CH), 7.80 (d, J = 7.5 Hz, 1H, 
aromatic CH), 11.75 (s, 1H, NH). Anal. (C17H16ClNO3S) C, H, N. 
2-[(4-Chlorobenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic acid 
(29). The title compound was prepared starting from ethyl 2-[(4-chlorobenzoyl)amino]-5,6,7,8-
tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate 2547 by Method C in 29% yield: mp  208-209 
°C; 1H-NMR (CDCl3) δ 1.60-1.70 (m, 4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 3.15-3.20 
(m, each 2H, cycloheptane CH2), 7.45-7.50 and 7.85-7.90 (d, J = 8.3 Hz, each 2H, aromatic CH),  
12.00 (s, 1H, NH). Anal. (C17H16ClNO3S) C, H, N. 
2-[(4-Methoxybenzoyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylic 
acid (30). The title compound was prepared starting from 26 by Method C in 32% yield: mp 187-
188 °C; 1H-NMR (CDCl3) δ 1.60-1.70 (m, 4H, cycloheptane CH2), 1.85-1.90, 2.75-2.80 and 3.15-
3.20 (m, each 2H, cycloheptane CH2), 3.90 (s, 3H, CH3), 6.95-7.00 and 7.90-7.95 (d, J = 8.5 Hz, 
each 2H, aromatic CH), 12.00 (s, 1H, NH). Anal. (C18H19NO4S) C, H, N. 
2-[(2-Fluorobenzoyl)amino]-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylic acid (36). 
The title compound was prepared starting from ethyl 2-[(2-fluorobenzoyl)amino]-5,6-dihydro-4H-
cyclopenta[b]thiophene-3-carboxylate 3548 by Method C in 63% yield: mp 219-220 °C; 1H-NMR 
(DMSO-d6) δ 2.25 (quintet, J = 7.5 Hz, 2H, cyclopentane CH2), 2.80 (q, J = 7.5 Hz, 4H, 
cyclopentane CH2), 7.35-7.45 (m, 2H, aromatic CH), 7.70 (dq, J = 1.4 and 7.3 Hz, 1H, aromatic 
CH), 8.00 (dt, J = 1.7 and 7.8 Hz, 1H, aromatic CH), 12.10 (d, J = 10.5 Hz, 1H, NH), 13.10 (bs, 1H, 
COOH); 13C-NMR (DMSO-d6) δ 27.8, 28.8, 30.2, 110.1, 117.2 (d, JC-F = 23 Hz) , 119.5 (d, JC-F = 
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11 Hz), 125.9, 132.0, 132.6, 135.5 (d, JC-F = 9 Hz), 142.2, 150.0, 159.3, 160.3 (d, JC-F = 247 Hz), 
166.9. Anal. (C15H12FNO3S) C, H, N. 
 
Biology  
Compounds and peptide. RBV (1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) was obtained 
from Roche. Each test compound was dissolved in DMSO 100%. The PB1(1–15)–Tat peptide was 
synthesized and purified by the Peptide Facility of CRIBI Biotechnology Center (University of 
Padua, Padua, Italy). This peptide possesses a C-terminal sequence from the HIV Tat protein 
(amino acids 47–59), which has been shown to mediate cell entry.53 
Plasmids. Plasmids pcDNA-PB1, pcDNA-PB2, pcDNA-PA, and pcDNA-NP, containing cDNA 
copies of the influenza A/PR/8/34 virus PB1, PB2, PA, and NP genes, respectively, were created as 
described elsewhere54 and kindly provided by P. Digard (Roslin Institute, University of Edinburgh, 
United Kingdom). Plasmid pPolI-Flu-ffLuc, which contains an influenza virus-based luciferase 
minireplicon vRNA under the control of the human RNA polymerase I promoter, was provided by 
L. Tiley (University of Cambridge, United Kingdom). Plasmid pRL-SV40 expressing the Renilla 
luciferase was purchased from Promega. 
Cells and Virus. Human Embryonic Kidney (HEK) 293T and Mardin-Darby canine kidney  
(MDCK) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Life Biotechnologies) 
supplemented with 10% (v/v) fetal bovine serum (FBS, Life Technologies) and antibiotics (100 
U/ml penicillin and 100 µg/ml streptomycin, Life Technologies).  The cells were maintained at 37 
°C in a humidified atmosphere with 5% CO2. Influenza A/PR/8/34 virus (H1N1, Cambridge 
lineage) was obtained from P. Digard (Roslin Institute, University of Edinburgh, United Kingdom). 
Influenza A/Wisconsin/67/05 was provided by R. Cusinato (Clinical Microbiology and Virology 
Unit, Padua University Hospital, Padua, Italy). The clinical isolate A/Parma/24/09 was kindly 
provided by I. Donatelli (Istituto Superiore di Sanità, Rome, Italy); local strains of the new 
pandemic variant H1N1 FluA virus (A/Padova/30/2011, A/Padova/72/2011, and 
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A/Padova/253/2011) were provided by C. Salata and A. Calistri (University of Padua, Padua, Italy). 
Influenza B/Lee/40 virus was obtained from W. S. Barclay (Imperial College, London, United 
Kingdom).  
Protein expression and purification. To obtain the 6His-PA(239-716) protein, the pET28a-PA239-
716 plasmid was transformed into E. coli strain BL21(DE3)pLysS (Stratagene). Typically, cells 
were grown in Luria Bertani (LB) medium containing 50 µg/ml kanamycin until the OD600 was 0.8 
and then induced by the addition of 0.5 mM isopropyl-ß-D-thiogalactopyranoside (IPTG, ICN) 
overnight (O/N) at 16 °C. Cells were pelleted, resuspended in 20 mM Tris-HCl pH 8.0, 500 mM 
NaCl, 500 mM urea, 10 mM ß-mercaptoethanol, 25 mM imidazole, 1 mg/ml lysozyme, and 
Complete protease inhibitors (Roche Molecular Biochemicals), and then lysed by two freeze/thaw 
cycles and by sonication. The lysate was centrifuged at 13,000 rpm for 30 min, applied to a 0.5-ml 
Ni-NTA agarose resin column (Qiagen) that had been equilibrated in resuspension buffer. Protein 
was eluted with 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 500 mM urea, 10 mM ß-mercaptoethanol, 
250 mM imidazole. The GST-PB1(1-25) fusion protein and GST alone were purified from E. coli 
BL21(DE3)/pLysS harboring the pD15-PB11-25 or pD15-GST plasmid, respectively. Cells were 
grown in LB medium containing 100 µg/ml ampicillin until the OD600 was 0.8 and then induced by 
the addition of 0.5 mM IPTG O/N at 16 °C. Cells were pelleted, resuspended in 50 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 20% glycerol, 5 mM DTT, 1 mg/ml lysozyme, and Complete protease 
inhibitors, and then lysed by two freeze/thaw cycles followed by sonication. The lysate was 
centrifuged at 13,000 rpm for 30 min, applied to a 0.5-ml glutathione-Sepharose 4 FastFlow column 
(Amersham Pharmacia Biotech) that had been equilibrated in lysis buffer. Finally, protein was 
eluted with 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 20% glycerol, 5 mM DTT, and glutathione 40 
mM. Both 6His-PA(239-716) and GST-PB1(1-25) purified proteins were dialyzed against 20 mM Tris-
HCl pH 8.0, 150 mM NaCl, 30% glycerol, 5 mM DTT and stored at -80 °C. 
PA-PB1 interaction enzyme-linked immunosorbent assay (ELISA). Microtiter plates (Nuova 
Aptca) were coated with 400 ng of purified 6His-PA(239-716) for 3 h at 37 °C and then blocked with 
31 
 
2% BSA (Sigma) in PBS for 1 h. After washes with PBS containing 0.3% Tween 20, 200 ng of 
GST-PB1(1-25), or GST alone as a control, in the absence or the presence of test compounds at 
various concentrations (10, 50, 100, 200 µM) were added and incubated O/N at RT. After washing, 
samples were incubated with horseradish peroxidase (HRP)-conjugated anti-GST monoclonal 
antibody (GenScript; diluted 1:3000 in PBS containing 2% FBS). Following washes with PBS plus 
0.3% Tween 20, the chromogenic substrate 3,3’,5,5’ tetramethylbenzidine (TMB, KPL) was added 
and absorbance was read at 450 nm on an ELISA plate reader (Tecan Sunrise™).  
Cytotoxicity assays. Cytotoxicity of compounds was tested in MDCK and HEK 293T cells by the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) method. Briefly, cells were 
seeded at a density of 2×104 per well into 96-well plates. The next day, cell medium was removed, 
and fresh medium containing DMEM plus test compounds at various concentrations (from 250 to 
1.9 µM) was added to each well. After 24 or 48 h for HEK 293T and MDCK cells, respectively, 5 
mg/ml of MTT solution was added to each well and plates were incubated for 4 h at 37 °C in a CO2 
incubator. Successively, a solubilization solution was added to lyse cells. After 3 h of incubation at 
37 °C, absorbance was measured at 620 nm using an ELISA plate reader (Tecan Sunrise™).  
Plaque reduction assays (PRA).  A confluent monolayer of MDCK cells was prepared in 12-well 
plates. Cells were infected with  the FluA or FluB virus at 40 PFU/well in DMEM supplemented 
with 1 µg/ml of TPCK-treated trypsin (Worthington Biochemical Corporation) and 0.14% BSA in 
the presence of various concentrations (0, 25, 50, 100 µM) of test compounds for 1 h at 37 °C. 
Medium containing 1 µg/ml of TPCK-treated trypsin, 0.14% BSA, 1.2% Avicel, and test 
compounds at the same concentrations was then added. After 2 days of incubation, cell monolayers 
were fixed with 4% formaldehyde and stained with 0.1% toluidine blue, and viral plaques were 
counted. 
Virus yield reduction assays. MDCK cells were seeded at a density of 2×105 cells per well in 24-
well plates. The next day, cells were infected with influenza A/PR/8/34 virus at an MOI of 0.01 in 
DMEM plus 0.14% BSA and 1 μg/ml TPCK-treated trypsin, in the presence of various 
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concentrations (0, 3, 10, 30, 100 µM) of test compounds for 1 h at 37 °C. Cells were then incubated 
with DMEM containing 1 µg/ml of TPCK-treated trypsin, 0.14% BSA, and test compounds at the 
same concentrations. At 12 h post-infection (p.i.), cell culture supernatants were collected and viral 
progeny was titrated by plaque assays on MDCK monolayers. 
Minireplicon assays. HEK 293T cells were seeded at a density of 105 per well into 24-well plates. 
After 24 h, cells were transfected with pcDNA-PB1, pcDNA-PB2, pcDNA-PA, pcDNA-NP 
plasmids (100 ng/well of each) along with pPolI-Flu-ffLuc plasmid (50 ng/well). The transfection 
mixture also contained pRL-SV40 plasmid (50 ng/well) to normalize variations in transfection 
efficiency. Transfections were performed using calcium phosphate protocol in the presence of the 
test compounds or DMSO. Cell medium was replaced 4 h post-transfection with DMEM containing 
compounds or DMSO. At 24 h post-transfection, cells were harvested and both firefly luciferase 
and Renilla luciferase expression were determined using the Dual Luciferase Assay Kit from 
Promega.  
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Table 1.  Structure and Biological Activity of the Compounds Synthesized in This Study. 
 
 
  
Cytotoxicity  
(MTT Assay) 
Compd 
 
ELISA 
PA-PB1 
Interaction 
Assay 
IC50, µMa 
PRA  
in MDCK 
cells 
EC50, µMb 
HEK 293T 
cells 
CC50, µMc 
MDCK  
cells 
CC50, µMc 
 n R’ R     
1  3 
 
 
145 ± 12 90 ± 13 >250 >250 
2 3 “ 
 
87 ± 11 >100 >250 >250 
3 3 “ 
 
>200 >100 >250 150 
4 3 “ 
 
99 ± 20 58 ± 7 >250 >250 
5 3 “ 
 
134 ± 21 39 ± 3 >250 >250 
6 3 “ 
 
32 ± 9 18 ± 2 >250 >250 
7 3 “ 
 
>200 23 ± 3 >250 >250 
8 3 “ 
 
>200 31 ± 5 231 ± 7 >250 
9 3 “ 
 
>200 20 ± 5 >250  180 ± 27 
40 
 
10 3 “ 
 
>200 16 ± 1 250 ± 16 >250 
11 3 “ 
 
>200 19 ± 3 >250 >250 
12 3 “ 
 
>200 19 ± 1 220 ± 16 >250 
13 3 “ 
 
>200 17 ± 2 >250 >250 
14 3 “ 
 
>200 >100 >250 >250 
15 3 “ 
 
>200 18 ± 1 >250 246 ± 5 
16 3 “ 
 
>200 21 ± 2 >250 >250 
17 3 “ 
 
48 ± 12 58 ± 11 >250 >250 
18 3 “ 
 
90 ± 22 61 ± 9 >250 >250 
19 3 “ H 35 ± 10 26 ± 4 >250 >250 
20 3 NH2 
 
>200 >100 >250 >250 
21 3 OEt “ 200 78 ± 3 >250 >250 
22 3 OH “ 200 76 ± 3 >250 >250 
23 3 OEt 
 
>200 91 ± 10 >250 >250 
24 3 OEt 
 
>200 94 ± 6 >250 >250 
25 3 OEt 
 
>200 89 ± 10 >250 >250 
26 3 OEt 
 
>200 95 ± 5 >250 >250 
27 3 OH 
 
>200 81 ± 16 >250 >250 
28 3 OH 
 
>200 79 ± 16 >250 >250 
29 3 OH 
 
>200 43 ± 6 >250 >250 
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30 3 OH 
 
>200 52 ± 10 >250 >250 
31 2 
 
 
>200 >100 60 ± 8 >250 
32 1 “ “ >200 >100 150 ± 8 >250 
33 2 NH2 “ >200 >100 31 ± 5 118 ± 12 
34 1 NH2 “ >200 >100 >250 >250 
35 1 OEt “ >200 >100 >250 >250 
36 1 OH “ 159 ± 15 77 ± 15 >250 >250 
RBV    8 ± 2 >250 >250 
Tat-PB11-15 
peptide   35 ± 3 40 ± 5 >100 >100
 
a Activity of the compounds in ELISA PA-PB1 interaction assays. The IC50 value represents the compound 
concentration that reduces by 50% the interaction between PA and PB1. b Activity of the compounds in plaque 
reduction assays with the FluA PR8 strain. The EC50 value represents the compound concentration that inhibits 50% of 
plaque formation. c Activity of the compounds in MTT assays. The CC50 value represents the compound concentration 
that causes a decrease of cell viability of 50%. All the reported values represent the means ± SD of data derived from 
at least three independent experiments in duplicate. 
  
 
Table 2. Activity of Selected 
Compounds on PR8 Virus Yield and 
Against Viral RNA Polymerase.
 
Compd 
Virus Yield 
Reduction Assay 
EC50, µMa 
Minireplicon 
Assay 
EC50, µMb 
6 12 ± 3 10 ± 2 
17 20 ± 6 67 ± 10 
18 6 ± 1 >100 
19 6 ± 1 14 ± 4 
RBV 2 ± 1 15 ± 7 
a This EC50 value represents the compound 
concentration that inhibits 50% of plaque 
formation. b This EC50 value represents the 
compound concentration that reduces by 50% the 
activity of FluA virus RNA polymerase in 293T 
cells. All data shown represent the means ± SD of 
data derived from at least two independent 
experiments in duplicate. 
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Table 3. Activity of Selected Compounds Against a 
Panel of Influenza A Virus Strains and Against 
Influenza B Virus. 
Virus strain 
Compound 
PRA (EC50, µM )a 
6 19 RBV 
A/PR/8/34 (H1N1) 18 ± 2 26 ± 4 8 ± 2 
A/Padova/30/2011 (H1N1) 20 ± 4 28 ± 5 7 ± 2 
A/Padova/72/2011 (H1N1) 19 ± 2 22 ± 3 6 ± 1 
A/Padova/253/2011 (H1N1) 21 ± 3 27 ± 2 11 ± 4 
A/Parma/24/09 (H1N1) 
(Oseltamivir-resistant) 23 ± 3 25 ± 1 17 ± 2 
A/Wisconsin/67/05 (H3N2) 15 ± 1 19 ± 2 12 ± 7 
B/Lee/40 21 ± 1 19 ± 1 6 ± 3 
a The EC50 value represents the compound concentration that 
inhibits 50% of plaque formation. All data shown represent the 
means ± SD of data derived from at least two independent 
experiments. 
 
 
 
 
Figure legends 
Figure 1. Hit compound previously identified by SBDD. 
Figure 2. A) Hydrophobic regions generated by GRID34 in the PA cavity from the x-ray structure 
reported by He and coworkers.28 The best docked poses generated by FLAP for compound 1 (B), 
compound 17 (C) and compound 18 (D) are also reported, after mild minimization. Residues that 
define the first (black), the second (red), and the third (blue) cavity as defined by Liu et al. are 
reported. Other residues discussed in the text are reported in green. 
Figure 3. A) Comparison between the crystallographic structure 3CM8 (light pink) and the 
dynamic snapshot (dark red) of PA.31 Hypothesis on the binding modes for compound 6 (B) and 
compound 19 (C) in the PA cavity as generated by FLAP, after mild minimization.  
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Scheme Footnotes 
Scheme 1.  
a Reagents and conditions: i) ammonium acetate, glacial acetic acid, benzene, reflux; ii) sulphur, 
N,N-diethylamine, EtOH, 40-50 °C; iii) acyl chlorides, pyridine; iv) ArCH2CO2H, DMTMM, THF, 
pyridine. 
Scheme 2. 
a Reagents and conditions: i) acyl chlorides, pyridine; ii) LiOH, H2O/THF, 50 °C. 
 
 
 
Figure 1 
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Figure 2.  
 
Figure 3 
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Scheme 1a 
 
 
 
 
Scheme 2a 
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Table S1. Elemental analysis data for target compounds  
 Calcd (%) Found (%) 
Compd C H N C H N 
1 64.53 4.92 10.26 64.63 4.90 10.27 
2 67.50 5.41 10.73 67.59 5.42 10.71 
3 64.53 4.92 10.26 64.62 4.93 10.24 
4 64.53 4.92 10.26 64.48 4.91 10.27 
5 62.04 4.73 9.87 62.18 4.75 9.83 
6 62.04 4.73 9.87 62.15 4.70 9.86 
7 59.52 4.31 9.47 59.62 4.29 9.50 
8 57.40 4.16 9.13 57.54 4.15 9.15 
9 66.47 6.85 10.57 66.38 6.83 10.61 
10 65.23 5.24 9.92 65.40 5.25 9.95 
11 62.79 5.04 9.55 62.85 5.06 9.52 
 12 68.12 5.72 10.36 68.27 5.94 10.39 
13 65.88 5.53 9.60 65.95 5.55 9.58 
14 67.12 7.10 10.21 67.30 7.13 10.18 
15 63.49 5.33 9.26 63.38 5.50 9.00 
16 68.71 6.01 10.02 68.80 6.03 9.98 
17 68.40 5.30 12.27 68.60 5.31 12.23 
18 63.52 5.13 8.55 63.61 5.15 8.57 
19 62.69 5.96 14.62 62.78 6.10 14.53 
20 61.43 5.16 8.43 61.31 5.14 8.46 
21 63.14 5.58 3.88 63.25 5.60 3.86 
22 61.25 4.84 4.20 61.43 4.81 4.18 
23 63.14 5.58 3.88 63.18 5.35 3.76 
24 60.39 5.33 3.71 60.45 5.31 3.72 
26 64.32 6.21 3.75 64.40 6.23 3.55 
27 61.25 4.84 4.20 61.41 4.85 4.21 
28 58.37 4.61 4.00 58.21 4.59 4.02 
29 58.37 4.61 4.00 58.49 4.80 3.97 
30 62.59 5.54 4.06 62.70 5.55 4.04 
31 63.78 4.59 10.63 63.90 4.61 10.59 
32 62.98 4.23 11.02 62.87 4.24 11.05 
36 59.01 3.96 4.59 59.16 3.98 4.60 
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Figure S1: FLAP binding poses for compounds 2, 4 and 5 (A, B and C, respectively).  
  
 
 
Based on our model the FLAP binding poses for compounds 2 (A) and 4 (B) are very similar,  thus 
the fluorine atom in para position does not induce a modification in the binding mode. This 
hypothesis is in agreement with the ELISA assay data, which are almost identical for the two 
compounds. Conversely compound 5 (Figure S1-C) shows a binding pose slightly different from 
the previous one. Although this compound possess a similar orientation, the hydrophobic MIF 
ligand-protein matches are not as good as for the other active compounds 2 and 4.  
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